Advertisement covers EACS 2013

Building a Better HIV Drug: Nano-Formulated Medicines

December 18, 2013


Benefits for Sustained Release of Antiretrovirals

Benefits for Sustained Release of Antiretrovirals

Since some nanomedicines can act as depots, releasing the active drug over an extended period of time, this can be beneficial for long-acting formulations of antiretrovirals, Owen said. For patients, this has the potential for drugs to be taken only once a month or longer. It also could result in formulations of PrEP (pre-exposure prophylaxis) that are easier to take and more practical as an extended means of HIV prevention.

However, currently only two such drugs are in development: long-acting rilpivirine, a monthly intramuscular injection, and an injectable formulation of the integrase inhibitor GSK744. Another current downside is that these drugs require an oral "lead-in" to mitigate adverse drug reactions.

This article was provided by It is a part of the publication The 14th European AIDS Conference (EACS 2013).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.